UCB's Global Corporate Website

This section is intended for media and financial analysts

Acquisition and disposal of own shares

Brussels (Belgium), 1 July 2022 – 20:00 (CEST) – Regulated information 

Acquisition of own shares

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV (“UCB” or the “Company) (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2022. 

Under this program, UCB has requested a financial intermediary to repurchase up to 500 000 UCB shares on its behalf under the terms of a discretionary mandate agreement with initial validity until 31 August 2022, effective as from 28 June 2022, to cover current and future obligations under UCB's Long Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2022, UCB repurchased 103 000 UCB shares on Euronext Brussels in the period from 28 June 2022 up to and including 30 June 2022, as follows:

For consistency reasons, UCB confirms that during the same period, it has not disposed of any UCB shares within the framework of the Long-Term Incentive Program of the UCB Group.

This press release is available on UCB SA/NV’s website via the following link.

For further information, contact UCB: 

Investor Relations Antje Witte  T +32 2 559 94 14 antje.witte@ucb.com

Corporate Communications Laurent Schots  T+32 2 559 92 64 laurent.schots@ucb.com    

About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Asset Download

Stay up-to-date on the latest news and information from UCB